Nonpeghylated liposomal doxorubicin combination regimen ( R‐COMP ) for the treatment of lymphoma patients with advanced age or cardiac comorbidity

Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center

(2019) José C. Jaime-Pérez et al.   HEMATOLOGICAL ONCOLOGY

Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP

(2019) E. Baudry et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines

(2018) Joachim Baech et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16)

(2018) Roosa Enni Inkeri Prusila et al.   HEMATOLOGICAL ONCOLOGY

Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience

(2017) Alessandra Fornaro et al.   EUROPEAN JOURNAL OF HEART FAILURE

Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis

(2017) Siew Lian Leong et al.   Scientific Reports

Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma

(2016) Michael A. Fridrik et al.   EUROPEAN JOURNAL OF CANCER

‘Real Life’experience in a ‘difficult to treat’patient population of non-Hodgkin lymphomas using the R-COMP regimen

(2016) Ombretta Annibali et al.   LEUKEMIA & LYMPHOMA

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

(2015) Folefac Aminkeng et al.   NATURE GENETICS

Genetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children

(2015) Henk Visscher et al.   PHARMACOGENOMICS

Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

(2015) Maja V Maraldo et al.   Lancet Haematology

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

(2014) J. Baselga et al.   ANNALS OF ONCOLOGY

Prevention of Anthracycline-Induced Cardiotoxicity

(2014) Pimprapa Vejpongsa et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma

(2014) Pier Luigi Zinzani et al.   LEUKEMIA & LYMPHOMA

Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation

(2013) Saro H. Armenian et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

(2013) Brian C Jensen et al.   PHARMACOGENOMICS

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

(2011) Gaetano Corazzelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

How we treat elderly patients with Hodgkin lymphoma

(2011) Magnus Björkholm et al.   CURRENT OPINION IN ONCOLOGY

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

(2011) Frédéric Peyrade et al.   LANCET ONCOLOGY

A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer

(2010) M. Venturini et al.   BREAST

Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial

(2010) Etienne G.C. Brain et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial

(2009) S. Luminari et al.   ANNALS OF ONCOLOGY

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy

(2008) R. Pettengell et al.   ANNALS OF HEMATOLOGY

Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane

(2008) Elly V. Barry et al.   JOURNAL OF CLINICAL ONCOLOGY

R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study

(2008) Giuseppe Visani et al.   LEUKEMIA & LYMPHOMA